Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FATE
SellHot AirFate Therapeutics, Inc. · Healthcare · United States · $291M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of programmed cellular immunotherapies, specifically induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T-cell product candidates for cancer and autoimmune diseases. Its innovative iPSC platform represents a differentiated approach to cell therapy manufacturing, offering potential for off-the-shelf treatments. The company is a key player in the nascent but rapidly evolving allogeneic cell therapy space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 96.3M | 63.5M | 13.6M | 6.6M | -59.0% | 6.5M | 5.6M | 4.8M | -15.3% |
| EPS | -2.91 | -1.64 | -1.64 | -1.15 | — | -1.05 | -1.02 | -0.97 | — |
| Shares | 97.3M | 98.6M | 113.9M | 115.4M | +18.6% | 119.8M | — | — | — |
| Debt | 109.3M | 103.5M | 85.3M | 77.8M | -10.7% | 75.7M | — | — | — |
| Equity | 483.9M | 368.4M | 318.7M | 207.2M | -24.6% | — | — | — | — |
| Op CF | -248.2M | -132.3M | -122.9M | -106.1M | — | -101.9M | — | — | — |
| Inv CF | 166.8M | 112.7M | 12.2M | 111.2M | — | — | — | — | — |
| Fin CF | 9.2M | 85.0K | 99.9M | 5.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FATE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc.(you) | $291M | 21 | Sell |
| IRD | Opus Genetics, Inc. | $307M | 22 | Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 19 | Strong Sell |
| IMRX | Immuneering Corporation | $323M | 19 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 17 | Strong Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $320M | 18 | Strong Sell |
| SABS | SAB Biotherapeutics, Inc. | $345M | 23 | Sell |
| MGNX | MacroGenics, Inc. | $263M | 17 | Strong Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $360M | 17 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%